Fast Acting Insulin Aspart Compared with Insulin Aspart in the Medtronic [amount hidden] Hybrid Closed Loop System in Type 1 Diabetes: An Open Label Crossover Study

What Was Tested

This randomized controlled trial paper looks at Insulin Aspart.

Each treatment period was 7 weeks and a standardized meal test was administered 6 weeks after the start of each treatment period.

The primary endpoint was postprandial glucose (PPG) increment after the meal test at 1 h.

Who Took Part

Forty patients were randomized to either IAsp or FA.

How the Study Was Run

In design terms this was a randomized, double-blind, open-label and crossover study.

Because people in this Insulin Aspart study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

As a double-blind Insulin Aspart study, the assignments were hidden from both participants and investigators until the end.

Nothing was hidden in this open-label Insulin Aspart study: the participants and staff both knew the treatment.

In the crossover set-up each of the participants took both Insulin Aspart and the comparison in turn, acting as their own control.

What Was Measured

Each treatment period was 7 weeks and a standardized meal test was administered 6 weeks after the start of each treatment period.

The primary endpoint was postprandial glucose (PPG) increment after the meal test at 1 h.

Topics PubMed links to this paper include Blood Glucose, Diabetes Mellitus, Type 1, Hypoglycemic Agents, Insulin and Insulin Aspart.

Author keywords: Fast acting insulin aspart and Type 1 diabetes.

What This Means in Plain Language

The paper is a randomized, double-blind and open-label study of Insulin Aspart.

The publication is from 2021 (Diabetes technology & therapeutics), a journal based in United States.

More context: the Insulin Aspart compound page, all human trials.